Vertex Pharmaceuticals (VX1) Stock Statistics & Valuation Metrics

Vertex Pharmaceuticals has a market cap or net worth of €105.29B. The enterprise value is €120.05B.

Vertex Pharmaceuticals has 253,718,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vertex Pharmaceuticals’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 18.12%.

The current PE Ratio of Vertex Pharmaceuticals is 31.0. Vertex Pharmaceuticals’s PEG ratio is -0.03.

In the last 12 months, Vertex Pharmaceuticals had revenue of 12.07B and earned 3.95B in profits. Earnings per share was 15.46.

In the last 12 months, operating cash flow was 3.72B and capital expenditures -380.80M, giving a free cash flow of 3.34B billion.

Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Vertex Pharmaceuticals upcoming earnings date is May 6, 2026, After Close (Confirmed).

Vertex Pharmaceuticals as a current ratio of 2.90, with Debt / Equity ratio of 20.80%

In the past 12 months, Vertex Pharmaceuticals has paid 690.00M in taxes.

Vertex Pharmaceuticals EV to EBITDA ratio is 23.09, with an EV/FCF ratio of 35.92.

Vertex Pharmaceuticals has €6.29B in cash and marketable securities with €1.83B in debt, giving a net cash position of €4.45B billion.

Gross margin is 86.28%, with operating margin of 39.43%, and net profit margin of 32.74%.

The average price target for Vertex Pharmaceuticals is €462.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy